PRP4 kinase Activators
PRP4 Kinase Activators are a diverse group of chemical compounds that, through various mechanisms, enhance the functional activity of PRP4 kinase within cellular signaling networks. Staurosporine, for example, despite being a broad-spectrum kinase inhibitor, can at specific dosages selectively activate PRP4 kinase by inhibiting other kinases that suppress PRP4 kinase activity. Similarly, Bisindolylmaleimide I, by targeting PKC, reduces phosphorylation-based inhibitory effects that are upstream of PRP4 kinase, leading to an increase in its activity. Forskolin indirectly contributes to the activation of PRP4 kinase by increasing cAMP levels, which subsequently activate PKA and can lead to the phosphorylation of substrates involvedin PRP4 kinase signaling. LY294002 and 5-Iodotubercidin both manipulate intracellular signaling molecules-PI3K and adenosine, respectively-thereby alleviating negative regulation on PRP4 kinase, resulting in its enhanced activity. MEK inhibitor U0126 and JNK inhibitor SP600125 act by inhibiting kinases that, when active, can suppress PRP4 kinase function; their inhibition thus indirectly promotes PRP4 kinase activity. Furthermore, SB203580's inhibition of p38 MAP kinase may activate alternative pathways that upregulate PRP4 kinase function as a compensatory response.
Sphingosine's role in the sphingolipid signaling pathway and its influence on kinase activity serve as a fundamental mechanism to bolster PRP4 kinase activity, while okadaic acid's inhibition of phosphatases PP1 and PP2A prevents the deactivation of PRP4 kinase, indirectly sustaining its active state. Anisomycin triggers stress response pathways, which can lead to the elevation of kinase signaling and putatively enhance PRP4 kinase activity. Lastly, the application of Phorbol 12-myristate 13-acetate (PMA) activates PKC, which can phosphorylate proteins within PRP4 kinase's signaling ambit, potentially resulting in an indirect enhancement of PRP4 kinase's functional role in cellular signaling cascades. Collectively, these compounds, through their targeted biochemical actions, serve as indirect activators of PRP4 kinase, emphasizing the intricate web of cellular signaling that governs protein kinase activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases. However, at low nanomolar concentrations, it can act as an indirect activator of PRP4 kinase by inhibiting competing kinases that negatively regulate PRP4 kinase activity, thereby promoting its kinase activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC) isoforms. By inhibiting PKC, which can phosphorylate substrates that negatively impact PRP4 kinase, this compound indirectly enhances the activity of PRP4 kinase by reducing inhibitory phosphorylation events. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, thereby increasing the levels of cAMP in cells. Elevated cAMP activates PKA, which can then phosphorylate and activate proteins that are part of the PRP4 kinase signaling cascade, indirectly enhancing PRP4 kinase activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. By inhibiting PI3K, it decreases AKT activity, which may negatively regulate PRP4 kinase via feedback loops. This reduction in AKT activity may lead to an indirect increase in PRP4 kinase activity. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $153.00 $464.00 | 20 | |
5-Iodotubercidin is an adenosine kinase inhibitor that can increase intracellular adenosine, which can subsequently inhibit kinases that negatively regulate PRP4 kinase, resulting in indirect activation of PRP4 kinase. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which phosphorylates targets that can regulate PRP4 kinase. Inhibition of JNK may relieve negative regulatory effects on PRP4 kinase, resulting in its indirect activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Inhibition of p38 may lead to the activation of alternate pathways that upregulate PRP4 kinase activity as a compensatory mechanism. | ||||||
D-erythro-Sphingosine | 123-78-4 | sc-3546 sc-3546A sc-3546B sc-3546C sc-3546D sc-3546E | 10 mg 25 mg 100 mg 1 g 5 g 10 g | $90.00 $194.00 $510.00 $2448.00 $9384.00 $15300.00 | 2 | |
Sphingosine is involved in the sphingolipid signaling pathway. It can modulate kinase activity and has been shown to activate certain protein kinases indirectly. Through these actions, sphingosine could enhance PRP4 kinase activity. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is an inhibitor of serine/threonine protein phosphatases PP1 and PP2A. By inhibiting these phosphatases, okadaic acid can prevent the dephosphorylation and inactivation of PRP4 kinase, indirectly maintaining it in an active state. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin acts as an inhibitor of protein synthesis and also activates stress-activated protein kinases. It could indirectly enhance PRP4 kinase activity by stimulating stress response pathways that upregulate kinase signaling. | ||||||